Vivo Capital and OrbiMed

Selected healthcare news for the capital firm - Vivo Capital, and the company - OrbiMed. We have 32 shared news items for this connection to-date. Based on the volume of shared news, it's source, placement and other factors, this connection is scored as strong.  Vivo Capital shares healthcare news with Preventice, Preventice Solutions, Biotech, OrbiMed and dozens of others. OrbiMed shares news with Biotech, COVID-19, Novartis, Digital Health, Cormorant Asset Management and hundreds of others.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/20/2021 Chinese Biotech Firm VISEN Raises $150m Led by Sequoia Capital China ... OrbiMed, HBM Healthcare Investments, Logos Capital and Cormorant Asset Management, Sherpa Healthcare Partners, Pivotal bioVenture Partners China, and CDG Capital. Existing backers Ascendis Pharma, Sofinnova Investments and Vivo Capital also re-upped in the round. The three investors jointly set up VISEN in 2018. Since its inception, the firm claims to be developing the unmet medical needs for patients who suffer from endocrine diseases in the Greater China region like ...
1/11/2021 VISEN Pharmaceuticals closes $150 million Series B financing ... OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as all of the existing investors, including Ascendis Pharma, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commercialisation.‚AuWe appreciate the confidence of our ...
1/9/2021 VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China ... OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commercialization."We appreciate the confidence ...
1/9/2021 VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China | Markets Insider Business Insider ... OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commercialization."We appreciate the confidence ...
1/9/2021 VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China ... OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commercialization."We appreciate the confidence ...
1/9/2021 VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China ... OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commercialization.‚AuWe appreciate the confidence ...
1/9/2021 VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China ... OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commercialization.‚AuWe appreciate the confidence ...
1/9/2021 The Ridgway Record ... OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commercialization."We appreciate the confidence ...
1/9/2021 VISEN Pharmaceuticals Closes $ 150 Million Series B Funding to Accelerate Development and Commercialization of Its Innovative Endocrinology Therapies in Greater China ... OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital and CDG Capital, as well as all existing investors, including Ascendis Pharma A / S , Vivo Capital and Sofinnova Investments. Proceeds from the Series B funding will be used to accelerate the clinical development of the best potential drug candidates in the portfolio and to build a solid foundation for commercialization.‚AuWe appreciate the confidence of our ...
1/8/2021 VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China - GuruFocus.com ... OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commercialization.NAS:ASND NAS:ASND ...
1/8/2021 VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China | Ask.com - What's Your Question? ... OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commercialization."We appreciate the confidence ...
1/5/2021 Terns Closes $87 Million Series C Financing to Advance NASH Portfolio | Business & Finance | manchestertimes.com Business Wire ... OrbiMed Advisors, Lilly Asia Ventures, Vivo Capital, Samsara Capital, Suvretta Capital Management and several other new investors. Elise Wang, Partner at Deerfield, has joined the Terns Pharmaceuticals Board of Directors.Terns plans to use the proceeds to advance clinical trials across its NASH pipeline and anticipates the following clinical milestones for its three lead NASH programs: TERN-101 (liver-directed non-bile acid farnesoid X receptor (FXR) agonist): top-line ...
1/5/2021 Terns Rakes in $87 Million for NASH Pipeline BioSpace ... OrbiMed Advisors, Lilly Asia Ventures and Vivo Capital.‚AuWe are impressed by the experienced team at Terns and their strategy of improving upon known mechanisms with differentiated molecules that have the potential to be used as foundational treatments in NASH,‚Au said Elise Wang, Partner at Deerfield. ‚AuWe look forward to Terns continuing its progress towards achieving its upcoming milestones in 2021 and beyond.Terns intends to utilize the funding ...
10/29/2020 Global clinical-stage cell therapy developer, ‚ÄúGenxi Bio‚Äù received a C round of 100 million US dollars financing Post Views: 2 Global clinicalstage cell therapy developer Genxi Bio received million dollars financingIt is reported that the biopharmaceutical company ‚AuGenxi Bio‚Au recently announced the completion of a $100 million Series C financing. This round of financing was led by Wellington Management Company, OrbiMed and Morningside Ventures. New investors participating in this round also include Vivo Capital. Existing investors Temasek Holdings, Lilly Asia Ventures, OrbiMed and King Star ...
10/28/2020 Gracell Biotechnologies Raises $100 Million in Series C Funding to Advance Next Generation CAR-T Cell Therapies PR Newswire SHANGHAI and SUZHOU, China Gracell Biotechnologies Inc. ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced it has secured $100 million in Series C funding. The round is led by Wellington Management Company, OrbiMed and Morningside Ventures, and joined by new investor Vivo Capital. Existing investors Temasek Holdings, Lilly Asia Ventures, OrbiMed and King Star Med ...
10/28/2020 Gracell Biotechnologies Raises $100 Million in Series C Funding to Advance Next Generation CAR-T Cell Therapies ... OrbiMed and Morningside Ventures, and joined by new investor Vivo Capital. Existing investors Temasek Holdings, Lilly Asia Ventures, OrbiMed and King Star Med LP are also participating."We are very pleased to expand our investor base with support from a high caliber consortium," said Dr. William Wei Cao , founder, Chairman, and CEO of Gracell, "Our passion is to bring transformative CAR-T cell therapies to a broader group of patients ...
8/31/2020 Terns Pharmaceuticals to Present at Upcoming Investor Conferences | Business & Finance | manchestertimes.com Business Wire ... OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital. For more information, visit www.ternspharma.com View source version on businesswire.com : https://www.businesswire.com/news/home/20200831005170/en/ CONTACT: Investor Relations Contact ...
8/31/2020 Terns Pharmaceuticals to Present at Upcoming Investor Conferences | Business & Finance | manchestertimes.com Business Wire ... OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital. For more information, visit www.ternspharma.com View source version on businesswire.com : https://www.businesswire.com/news/home/20200831005170/en/ CONTACT: Investor Relations Contact ...
8/11/2020 Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results Globe Newswire ... OrbiMed, RA Capital Management, and Vivo Capital, along with other healthcare-focused institutional investors. These new investors in the financing, along with Deerfield Management, the company’s largest pre-financing investor, and Atlas Ventures created a strong institutional shareholder base for the company. Together with approximately $40 million in cash on Zafgen’s balance sheet at the time of the merger, the combined company had approximately $116 million in cash immediately following ...
7/17/2020 Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription London Stock Exchange:VRP Globe Newswire ... OrbiMed, New Enterprise Associates (NEA), Vivo Capital, Abingworth, Novo Holdings A/S, Polar Capital and Aisling Capital also participated. Jefferies LLC (“Jefferies”) is acting as the lead placement agent to the Company in connection with the Financing. Verona Pharma intends to use the net proceeds from the Financing primarily to fund its Phase 3 clinical program ENHANCE ( E nsifentrine as a N ovel in HA led N ebulized C OPD ...
7/17/2020 Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription London Stock Exchange:VRP Globe Newswire ... OrbiMed, New Enterprise Associates (NEA), Vivo Capital, Abingworth, Novo Holdings A/S, Polar Capital and Aisling Capital also participated. Jefferies LLC (“Jefferies”) is acting as the lead placement agent to the Company in connection with the Financing. Verona Pharma intends to use the net proceeds from the Financing primarily to fund its Phase 3 clinical program ENHANCE ( E nsifentrine as a N ovel in HA led N ebulized C OPD ...
7/17/2020 Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription London Stock Exchange:VRP Globe Newswire ... OrbiMed, New Enterprise Associates (NEA), Vivo Capital, Abingworth, Novo Holdings A/S, Polar Capital and Aisling Capital also participated. Jefferies LLC (“Jefferies”) is acting as the lead placement agent to the Company in connection with the Financing. Verona Pharma intends to use the net proceeds from the Financing primarily to fund its Phase 3 clinical program ENHANCE ( E nsifentrine as a N ovel in HA led N ebulized C OPD ...
5/29/2020 Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics Globe Newswire ... OrbiMed, RA Capital Management, and Vivo Capital, along with other healthcare-focused institutional investors. Along with the company’s largest existing investor, Deerfield Management, the new investors in the financing create a strong institutional shareholder base for the company. Together with approximately $40 million in cash on Zafgen’s balance sheet at the time of the merger, the combined company has approximately $116 million in cash. On May 28, 2020, prior to ...
4/2/2020 RemeGen Completes USD $100 Million Plus in Funding PR Newswire YANTAI, China , April 2, 2020 /PRNewswire/ -- RemeGen recently announced the closing of approximately USD $100 million in a private financing co-led by Lilly Asia Ventures and Lake Bleu Capital. This round of investment is supported by well-known global institutional investors such as Vivo Capital, Janchor Partners, OrbiMed, Hudson Bay Capital and the company's existing investors. Loyal Valley Capital and China Reform Conson Soochow Overseas Fund also invested through ...
4/2/2020 RemeGen Completes USD $100 Million Plus in Funding PR Newswire YANTAI, China , April 2, RemeGen recently announced the closing of approximately USD $100 million in a private financing co-led by Lilly Asia Ventures and Lake Bleu Capital. This round of investment is supported by well-known global institutional investors such as Vivo Capital, Janchor Partners, OrbiMed, Hudson Bay Capital and the company's existing investors. Loyal Valley Capital and China Reform Conson Soochow Overseas Fund also invested through the purchase ...